Trinity J. Bivalacqua
MD, PhD, Associate Professor of Urology and Oncology, Johns Hopkins Medical Institutions
Trinity J. Bivalacqua, M.D., Ph.D., Associate Professor of Urology, Surgery, and Oncology, was born in New Orleans, Louisiana and graduated from Tulane University with undergraduate, graduate and medical degrees. He joined the faculty after completing his General Surgery and Urology training at Johns Hopkins Hospital. He also completed an American Urological Association (AUA) Foundation Fellowship.
Dr. Bivalacqua is the Director of Urologic Oncology and Co-Director of the Bladder Cancer Multidisciplinary Clinic. As a member of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dr Bivalacqua participates in multidisciplinary approaches to the treatment of a variety of genitourinary cancers. He has a special interest in cancers of the prostate and bladder with an emphasis on organ sparing therapies, minimally invasive techniques (nerve-sparing robotic assisted laparoscopic radical prostatectomy and robotic-assisted laparoscopic radical cystectomy) and orthotopic bladder substitution (neobladder). He also sees patients with advanced and rare urologic malignancies including sarcomas, penile and urethral cancer. Although he has a busy surgical practice, he maintains an active research portfolio in order to improve the care of cancer patients. A major focus of his research lab is to develop novel molecular-based targeted therapies for bladder cancer and preservation of erectile function in prostate cancer patients undergoing radical prostatectomy using novel agents.
Dr. Bivalacqua’s basic, translational and clinical research is funded by peer-reviewed awards and he has recently been acknowledged for his accomplishments in research with several grants including a Career Development Award from the National Institute of Health (NIH), the Patrick C. Walsh Prostate Cancer Research Fund, and the American Urological Association (AUA)Rising Star Award. He serves as Principal investigator for clinical trials in both prostate and bladder cancer including the only tissue engineered bladder cancer clinical trial in this country.
Click here for more information.